We are pleased to announce the launch of UTIPRO® PLUS AF in Portugal. Portugal is the first European country in which UTIPRO® PLUS AF has been launched in its composition free from ingredients of animal origin. The product is distributed by Sangool, a Portuguese company specialized in the detailing and the [...]
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants. XILAPLUS® is a class III medical device and complies with the [...]
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland. UTIPRO® PLUS AF, in its composition free from ingredients of animal origin, has been recently launched in the Republic of Ireland, thus further enlarging its presence across Europe. The product is distributed by Pamex, [...]
Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. [...]
We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and in the prevention of recurrences in uncomplicated UTIs The trial “Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults“ has [...]
Elena D Serban & Mihai Manolache; Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Publication of a retrospective, observational study on Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis. Aim: To evaluate the effectiveness and safety of gelatin tannate [...]
Allegrini A et al. Current Medical Research and Opinion 2017. June 10: 1-17 Background: This study assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray in the treatment of symptoms of rhinosinusitis. Methodology: In this randomized, double-blind study, 40 patients with itching, nasal congestion or continuous sneezing and [...]
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands. An observational study showing significant symptoms´ improvement in patients with IBS-D treated with Gelsectan® in [...]
HeleneEutamene, FannyPlacide, ValerieTondereau, VassiliaTheodorou https://doi.org/10.1016/S0016-5085(18)33080-4 BACKGROUND: Irritable Bowel Syndrome (IBS) is a common disorder characterized by visceral hypersensitivity and increased intestinal permeability. Stressful events can affect the onset and course of IBS. In rats, stress also induces visceral hypersensitivity and gut hyperpermeability. Mucoprotectant agents such as gelatin tannate and xyloglucan, [...]
We are pleased to announce the launch of Rhinosectan® in its first market, Spain. Rhinosectan® is based on Xyloglucan, a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa, and it is specifically formulated to control and treat the symptoms of rhinitis and rhinosinusitis from different aetiologies, [...]